{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-064022","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.678249+00:00","generated_at":"2026-06-01T09:20:35.782228+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Candel reports Phase 2 CAN-2409 data: 20.6-month median OS in NSCLC patients with ICI resistance","bullets":["Median overall survival of 20.6 months in NSCLC patients with progressive disease despite ICI, vs 11.6 months historical SoC docetaxel.","mOS of 22.0 months across all 46 patients with inadequate ICI response.","71.4% of evaluable metastatic patients had beneficial effect on both injected and uninjected tumors (abscopal response).","Increased circulating CD8+ and CD4+ memory T cells after second injection correlated with prolonged survival.","Favorable safety: no grade 4+ TRAEs; three grade 3 events (1 pyrexia, 2 pneumonitis)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-064022","json":"https://secwatch.observer/filing/0000950170-24-064022.json","markdown":"https://secwatch.observer/filing/0000950170-24-064022.md","text":"https://secwatch.observer/filing/0000950170-24-064022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024064022/0000950170-24-064022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024064022/cadl-20240523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:20:35.782228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}